Alendronate Sodium
Product Images NDC 67296-1500

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 67296-1500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

Chemical structure diagram of alendronate sodium showing its molecular components, including amine, carbon, phosphate groups, and sodium with associated water molecules (3H2O).*

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

A line graph depicting the cumulative incidence percentage of hip fractures over a three-year period in a study of patients with baseline radiographic vertebral fractures. It compares two groups: placebo (dashed line) and Alendronate Sodium (solid line), showing cumulative incidence on the y-axis and time in months on the x-axis.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

Bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal women' showing the increase in bone mineral density (BMD) after three years of Alendronate Sodium 10 mg/day treatment. The chart compares mean percent increase in BMD relative to placebo ± standard error for lumbar spine, femoral neck, and trochanter regions between U.S. and multinational study groups.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

This image contains two line graphs from osteoporosis treatment studies in postmenopausal women, showing the time course of lumbar spine bone mineral density (BMD) percent change from baseline. One graph is labeled 'US Study' and the other 'Multinational Study.' Both compare Alendronate Sodium 10 mg/day versus placebo over 0, 12, 24, and 36 months, with BMD percentage change on the vertical axis.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

This figure presents two bar charts comparing the mean percentage change in bone mineral density (BMD) from baseline over 2-year and 3-year osteoporosis prevention studies in postmenopausal women. The charts separate BMD changes at lumbar spine, femoral neck, trochanter, and total body sites, comparing Alendronate Sodium 5mg/day with placebo groups.*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

A bar chart comparing mean percent increase in Bone Mineral Density (BMD) relative to placebo at one year for glucocorticoid-treated patients taking Alendronate Sodium 5 mg/day. Data is shown for three anatomical sites: lumbar spine, femoral neck, and trochanter, with two groups labeled U.S. and Multinational.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

A line chart titled 'Studies in Paget's Disease of Bone' showing the effect on serum alkaline phosphatase of Alendronate Sodium 40 mg/day versus placebo or Etidronate 400 mg/day over a 6-month period. The y-axis represents serum alkaline phosphatase mean percentage change from baseline, and the x-axis represents time in months. Four groups are plotted: Placebo, Etidronate 400 mg/day, Alendronate Sodium 40 mg/day from a multinational study, and Alendronate Sodium 40 mg/day from a U.S. study, each with sample sizes noted.*

FDA Label Image

Cipla-35mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 08)

Packaging label for Alendronate Sodium Tablets USP 35 mg, a once weekly oral medication. The label includes instructions for removing tablets from the blister card, storage conditions, dosage information, and a warning for the pharmacist to dispense the accompanying Medication Guide. The product is labeled for prescription use and manufactured by Cipla under RedPharm Drug, Inc, with an NDC of 69097-223-16, containing 1 blister of 4 tablets.*

FDA Label Image

Cipla-70mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 09)

ALENDRONATE SODIUM 70 mg tablets label by RedPharm Drug, Inc. The label states the product is a once weekly oral tablet in USP strength. It includes instructions for use and tablet removal, storage guidelines, and manufacturer information. The label displays dosage strength prominently in green and black text with branding by Cipla, along with NDC 69097-224-16 and Rx only designation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.